4.7 Article

Early diagnosis of Alzheimers disease using cortical thickness: impact of cognitive reserve

期刊

BRAIN
卷 132, 期 -, 页码 2036-2047

出版社

OXFORD UNIV PRESS
DOI: 10.1093/brain/awp105

关键词

Early Alzheimers disease; individual diagnosis; mild cognitive impairment; magnetic resonance imaging (MRI); cognitive reserve

资金

  1. Alzheimer's disease Neuroimaging Initiative
  2. National Institutes of Health [U01 AG024904]
  3. National Institute on Aging
  4. National Institute of Biomedical Imaging and Bioengineering
  5. Pfizer Inc.
  6. Wyeth ResearchBristol-Myers Squibb
  7. Eli Lilly and Company
  8. GlaxoSmithKline
  9. Merck Co. Inc.
  10. AstraZeneca AB
  11. Novartis Pharmaceuticals Corporation
  12. Alzheimer's Association
  13. Eisai Global Clinical Development
  14. Elan Corporation plc
  15. Forest Laboratories
  16. Institute for the Study of Aging
  17. U. S. Food and Drug Administration
  18. Foundation for the National Institutes of Health

向作者/读者索取更多资源

Brain atrophy measured by magnetic resonance structural imaging has been proposed as a surrogate marker for the early diagnosis of Alzheimers disease. Studies on large samples are still required to determine its practical interest at the individual level, especially with regards to the capacity of anatomical magnetic resonance imaging to disentangle the confounding role of the cognitive reserve in the early diagnosis of Alzheimers disease. One hundred and thirty healthy controls, 122 subjects with mild cognitive impairment of the amnestic type and 130 Alzheimers disease patients were included from the ADNI database and followed up for 24 months. After 24 months, 72 amnestic mild cognitive impairment had converted to Alzheimers disease (referred to as progressive mild cognitive impairment, as opposed to stable mild cognitive impairment). For each subject, cortical thickness was measured on the baseline magnetic resonance imaging volume. The resulting cortical thickness map was parcellated into 22 regions and a normalized thickness index was computed using the subset of regions (right medial temporal, left lateral temporal, right posterior cingulate) that optimally distinguished stable mild cognitive impairment from progressive mild cognitive impairment. We tested the ability of baseline normalized thickness index to predict evolution from amnestic mild cognitive impairment to Alzheimers disease and compared it to the predictive values of the main cognitive scores at baseline. In addition, we studied the relationship between the normalized thickness index, the education level and the timeline of conversion to Alzheimers disease. Normalized thickness index at baseline differed significantly among all the four diagnosis groups (P 0.001) and correctly distinguished Alzheimers disease patients from healthy controls with an 85 cross-validated accuracy. Normalized thickness index also correctly predicted evolution to Alzheimers disease for 76 of amnestic mild cognitive impairment subjects after cross-validation, thus showing an advantage over cognitive scores (range 6372). Moreover, progressive mild cognitive impairment subjects, who converted later than 1 year after baseline, showed a significantly higher education level than those who converted earlier than 1 year after baseline. Using a normalized thickness index-based criterion may help with early diagnosis of Alzheimers disease at the individual level, especially for highly educated subjects, up to 24 months before clinical criteria for Alzheimers disease diagnosis are met.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据